What is the current Arbutus Biopharma Corporation (ABUS) stock price?

Arbutus Biopharma Corporation (NASDAQ: ABUS) stock price is $4.45 in the last trading session. During the trading session, ABUS stock reached the peak price of $4.48 while $4.42 was the lowest point it dropped to. The percentage change in ABUS stock occurred in the recent session was 0.34% while the dollar amount for the price change in ABUS stock was $0.02.

ABUS's industry and sector of operation?

The NASDAQ listed ABUS is part of Biotechnology industry that operates in the broader Healthcare sector. Arbutus Biopharma Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ABUS?

Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C.Sec.Mr. J. Christopher NaftzgerGen. Counsel & Chief Compliance OfficerMr. William H. CollierPres, Chief Executive Officer & DirectorMr. David C. Hastings CPAChief Financial Officer & Chief Accounting OfficerDr. Elizabeth HowardExecutive Vice President, Gen. Counsel, Chief Compliance Officer & Sec.Dr. Michael J. Sofia Ph.D.Chief Scientific OfficerMs. Lisa M. CaperelliVice President of Investor RelationsDr. Gaston Picchio Ph.D.Chief Devel. OfficerMr. Michael J. McElhaughChief Operating Officer & Chief Bus. OfficerDr. Elizabeth Howard J.D., Ph.D.Executive Vice President, Gen. Counsel, Chief Compliance Officer & Sec.Mr. Christopher NaftzgerGen. Counsel & Chief Compliance OfficerDr. Karen Sims M.D., Ph.D.Chief Medical OfficerKaren SimsVice President of Clinical Devel.Mr. J. Christopher Naftzger BA, Esq., J.D.Gen. Counsel & Chief Compliance Officer

How ABUS did perform over past 52-week?

ABUS's closing price is 50.68% higher than its 52-week low of $2.94 where as its distance from 52-week high of $5.10 is -13.14%.

How many employees does ABUS have?

Number of ABUS employees currently stands at 44.

Link for ABUS official website?

Official Website of ABUS is: https://www.arbutusbio.com

How do I contact ABUS?

ABUS could be contacted at phone 267 469 0914 and can also be accessed through its website. ABUS operates from 701 Veterans Circle, Warminster, PA 18974, United States.

How many shares of ABUS are traded daily?

ABUS stock volume for the day was 237.51K shares. The average number of ABUS shares traded daily for last 3 months was 2.19M.

What is the market cap of ABUS currently?

The market value of ABUS currently stands at $868.90M with its latest stock price at $4.45 and 195.48M of its shares outstanding.

Arbutus Biopharma Stock Price Today

Filing Date

Accepted Date

Filing Date

Accepted Date

Date	Open	High	Low	Close	Volume
Apr 21, 2026	4.60	4.63	4.42	4.43	891.31K
Apr 20, 2026	4.71	4.71	4.59	4.60	872.64K
Apr 17, 2026	4.68	4.75	4.60	4.72	1.05M
Apr 16, 2026	4.47	4.74	4.43	4.68	2.22M
Apr 14, 2026	4.36	4.45	4.32	4.35	1.36M
Apr 13, 2026	4.14	4.38	4.13	4.37	1.39M
Apr 10, 2026	4.31	4.33	4.13	4.15	2.67M
Apr 09, 2026	4.32	4.42	4.25	4.30	1.87M
Apr 08, 2026	4.58	4.60	4.35	4.38	1.97M
Apr 07, 2026	4.41	4.47	4.35	4.46	841.14K
Apr 06, 2026	4.47	4.60	4.46	4.46	696.17K
Apr 02, 2026	4.40	4.54	4.37	4.48	611.67K
Apr 01, 2026	4.54	4.62	4.47	4.52	1.2M
Mar 31, 2026	4.37	4.57	4.37	4.50	2.06M
Mar 30, 2026	4.28	4.35	4.21	4.30	1.07M
Mar 27, 2026	4.42	4.55	4.28	4.29	1.38M
Mar 25, 2026	4.40	4.64	4.39	4.53	2.55M
Mar 24, 2026	4.32	4.38	4.22	4.31	1.55M
Mar 23, 2026	4.36	4.60	4.24	4.42	7.62M
Mar 20, 2026	4.36	4.42	4.18	4.24	3.73M

Date

Open

High

Low

Volume

Apr 21, 2026

4.60

4.63

4.42

4.43

891.31K

Apr 20, 2026

4.71

4.59

4.60

872.64K

Apr 17, 2026

4.68

4.75

4.60

4.72

1.05M

Apr 16, 2026

4.47

4.74

4.43

4.68

2.22M

Apr 14, 2026

4.36

4.45

4.32

4.35

1.36M

Apr 13, 2026

4.14

4.38

4.13

4.37

1.39M

Apr 10, 2026

4.31

4.33

4.13

4.15

2.67M

Apr 09, 2026

4.32

4.42

4.25

4.30

1.87M

Apr 08, 2026

4.58

4.60

4.35

4.38

1.97M

Apr 07, 2026

4.41

4.47

4.35

4.46

841.14K

Apr 06, 2026

4.47

4.60

4.46

696.17K

Apr 02, 2026

4.40

4.54

4.37

4.48

611.67K

Apr 01, 2026

4.54

4.62

4.47

4.52

1.2M

Mar 31, 2026

4.37

4.57

4.37

4.50

2.06M

Mar 30, 2026

4.28

4.35

4.21

4.30

1.07M

Mar 27, 2026

4.42

4.55

4.28

4.29

1.38M

Mar 25, 2026

4.40

4.64

4.39

4.53

2.55M

Mar 24, 2026

4.32

4.38

4.22

4.31

1.55M

Mar 23, 2026

4.36

4.60

4.24

4.42

7.62M

Mar 20, 2026

4.36

4.42

4.18

4.24

3.73M

Company Overview

Arbutus Biopharma Corporation (NASDAQ:ABUS) closed at $4.45 USD, gaining $0.02 (0.34%) from the previous close of $4.43. The stock is currently mid-range between its 52-week high and low $2.94 and $5.10. With a market capitalization of about $868.90 million, Arbutus Biopharma Corporation is classified as a small-cap and shows lower-than-market volatility (beta ~0.74). Key stats such as the average daily volume over the past year has been around 2.19 million shares, volume is running light vs its 52-week average. Headquartered in Warminster, PA, Arbutus Biopharma Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Lindsay Androski, the company employs approximately 44 people and listed since July 26, 2007. Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States.

Technical Performance

ABUS has shown weak momentum, losing -6.56% over the past week and -4.65% over the past quarter, though year-to-date performance is down -12.58%. Short-term trend indicators are mixed aligned (SMA20 12.62%, SMA50 6.87%, SMA200 17.47%). The stock’s 14-day RSI is 64.07 (firm momentum), while the ATR of 0.26 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.84% below its high and over 73.75% above its low. Average 10-day trading volume of 1.30 million shares is below the 3-month average of 1.87 million, indicating normal recent market interest.

Valuation Metrics

Arbutus Biopharma Corporation trades at a P/E ratio of -25.51, slightly below the S&P 500 average, with a price-to-sales ratio of 61.91 and a price-to-book ratio of 11.16 reflecting a rich premium to book value. The P/FCF stands at -22.0, also below market averages. Compared to sector medians, Arbutus Biopharma Corporation P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Arbutus Biopharma Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.94. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Arbutus Biopharma Corporation generated EPS of -$0.22 over the past year. Five-year average earnings growth is 33.46%. The latest quarter delivered EPS of -$0.04. The next quarter is forecast at -$0.04. Next year's EPS is expected at $1.79. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $5.00. The high target offers 12.87% upside. The low target suggests 12.87% downside. The mean target is $5.00. This offers 12.87% upside. Arbutus Biopharma Corporation earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -12.24%. The prior quarter beat by -150.0%. Over the last six quarters, Apple has recorded several small beats. These include 10.0% in August 01, 2024.

Shareholding & Insider Activity

Arbutus Biopharma Corporation has 195.48 million shares outstanding. The public float is 127.68 million shares, elevated short interest at 12.08% of float. This equals 16.41 million shares. The short ratio is 6.27 days. Institutional investors hold 80.1% of the float. Insiders own 21.8%. Sofia Michael J. holds 1.49 million shares, McElhaugh Michael J. has 1.48 million shares and Machado Patrick has 1.16 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Arbutus Biopharma generated $18.14M in revenue, or $0.11 per share. Gross margin was 92.26%, operating margin -430.15%, and net profit margin -401.57%. Returns are negative, with ROA at -50.45% and ROE at -68.71%.
On valuation metrics, Arbutus Biopharma trades at a P/E of -25.51, P/S of 61.91 and P/B of 11.16. The current ratio is 15.73 and quick ratio is 15.73. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -2.39 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.05, supported by a cash flow-to-debt ratio of -9.46.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Arbutus Biopharma posted revenue of $18.14M, down slightly from $39.02M in the prior quarter. Gross profit was $16.74M (margin 92.26%). Operating income was - $78.03M (margin -430.2%). Net income was- $72.85M (EPS - $0.44).
The company ended the quarter with $126.00M in cash and short-term investments, a total debt of $8.72M, and net debt of - $17.56M. Total assets were $144.40M, with equity of $106.02M. Financials further reflected weakness, with operating cash flow of - $85.94M, free cash flow of - $86.94M, and capital expenditures of - $1.01M.

Price Forecast & Outlook

Our AI price prediction model suggests that Arbutus Biopharma Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.93%, with price expected at $4.56 by May 05, 2026, within a range of $4.38 to $4.71 3-Month Outlook: Projected rise of 16.7%, reaching $5.17 by July 20, 2026, with a range of $5.05 to $5.30. 1-Year Outlook: Projected gain of 483.75%, with price at $25.86 by April 21, 2027, within a range of $26.82 to $27.56.

Key Takeaways

Arbutus Biopharma Corporation (NASDAQ:ABUS) shares are down -12.58% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Arbutus Biopharma Corporation trading at a premium to the broader market with a P/E of -25.51. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.27, suggesting 41.53% upside. Our AI forecast model points to short-term strength (2.93% over two weeks), a medium-term rise (16.7% over three months), and a longer-term gain (483.75% over one year), with expected trading ranges indicating moderate volatility.

Employees	44
Beta	0.74
Sales or Revenue	$18.14M
5Y Sales Change%	0.025%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ABUS Company Profile and Key Details